Board of Directors

Beth Seidenberg, MD

Partner, Kleiner Perkins Caufield & Byers

Carl L. Gordon, PhD, CFA

Partner, OrbiMed

Xiangmin Cui, PhD

Founder and Managing Director, Decheng Capital

Naiyer Rizvi, MD

Director of Thoracic Oncology and Co-Director of Cancer Immunotherapy, Columbia University

Pierre Legault

Independent Director

Stella Xu, PhD

Managing Director, Quan Capital

Peter Van Vlasselaer, PhD

Founder, President and Chief Executive Officer, ARMO BioSciences


Beth Seidenberg, MD

Partner, Kleiner Perkins Caufield & Byers

Beth Seidenberg, M.D. has served as a member of our board of directors since December 2012. Dr. Seidenberg has been a partner at Kleiner Perkins (KP) since May 2005. Prior to joining KP, she was senior vice president, global development, and chief medical officer at Amgen, Inc. from January 2002 to January 2005. Prior to joining Amgen, Dr. Seidenberg was a senior executive in research and development at Bristol-Myers Squibb Company from March 2000 to December 2001 and Merck & Co. from June 1989 to February 2000. Dr. Seidenberg received her B.S. from Barnard College and her M.D. from the University of Miami School of Medicine. Her post-graduate training was completed at Johns Hopkins, George Washington School of Medicine and the National Institutes of Health. We believe Dr. Seidenberg is able to make valuable contributions to our board of directors due to her training as a physician, as well as her experience in the life sciences industry both as a senior executive and venture capitalist.

Carl L. Gordon, PhD, CFA

Partner, OrbiMed

Carl Gordon, Ph.D. has served as a member of our board of directors since December 2012. Dr. Gordon has been a partner and co-head of global private equity at OrbiMed Advisors since January 1998. Dr. Gordon serves as a director on the board of Arsanis, Inc., a publicly-traded healthcare company. Previously, Dr. Gordon served on the boards of Acceleron Pharma, Inc., Amarin Corporation, Intellia Therapeutics, Inc., Pacira Pharmaceuticals, Inc. and Selecta Biosciences Inc. Dr. Gordon received an A.B. in Chemistry from Harvard College and a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology. We believe Dr. Gordon is able to make valuable contributions to our board of directors due to his educational background in sciences, as well as financial understanding of the biotechnology industry gained from over two decades of venture capital experience.

Xiangmin Cui, PhD

Founder and Managing Director, Decheng Capital

Xiangmin Cui, Ph.D. has served as a member of our board of directors since August 2017. Dr. Cui is the founder of Decheng Capital China Life Sciences USD Fund II, L.P. and has served as its managing director since December 2011. Prior to that, Dr. Cui served as an investment partner at Bay City Capital. Dr. Cui co-founded Pan Pacific Pharmaceuticals and Hucon Biopharmaceuticals, focusing on the discovery and development of technologies in the fields of oncology, cardiology, infectious and inflammatory disease. Dr. Cui received his B.S. and M.S. in Molecular Biology from Peking University and his Ph.D. in Cancer Biology from Stanford University. We believe Dr. Cui is able to make valuable contributions to our board of directors due to his experience in the life science industry as a senior executive and as an investor.

Naiyer Rizvi, MD

Director of Thoracic Oncology and Co-Director of Cancer Immunotherapy, Columbia University

Naiyer Rizvi, M.D. has served as a member of our board of directors since June 2017. Dr. Rizvi has served as the director of Thoracic Oncology and co-director of Cancer Immunotherapy in the division of hematology and oncology at Columbia University Medical Center since January 2015, where he holds the Price Chair in Clinical Translational Research. Dr. Rizvi has also served as a medical oncologist at Columbia University Medical Center since January 2015, with specific expertise in the treatment of lung cancer, development of immunotherapy drugs, and translational research in immunotherapy. Prior to joining Columbia University Medical Center, Dr. Rizvi conducted clinical and translational research at Memorial Sloan Kettering Cancer from July 2002 to December 2014. He is also a scientific co-founder of Gritstone Oncology. Dr. Rizvi received his M.D. from the University of Manitoba, Faculty School of Medicine, where he also completed his residency. We believe Dr. Rizvi is able to make valuable contributions to our board of directors due to his training as a physician and the depth of his research experience in immunotherapy.

Pierre Legault

Independent Director

Pierre Legault has served as a member of our board of directors since April 2017. Mr. Legault served as chief executive officer of NephroGenex, Inc. from 2014 to 2016 and has served as the chairman of its board since 2012. Prior to that, Mr. Legault served as the chief executive officer of Prosidion Ltd. from 2010 to 2012. Mr. Legault also previously held various positions at OSI Pharmaceuticals, Rite Aid Corporation, Eckerd Group and Sanofi-Aventis U.S. LLC. Mr. Legault has also served on the boards of Syndax Pharmaceuticals Inc. since January 2017, Poxel SA since March 2016, Iroko Pharmaceuticals Inc from March 2015 to August 2017, Tobira Therapeutics, Inc. from December 2013 to November 2016, and Regado Biosciences, Inc. from March 2012 to December 2013, each a publicly traded company. Mr. Legault received his B.B.A. in Finance, Marketing and Accounting from The University of Montreal (HEC), his M.B.A. from McGill University and completed an executive master program in Information Technology at Harvard Business School. We believe Mr. Legault is able to make valuable contributions to our board of directors due to the breadth and depth of his experience in the life sciences industry.

Stella Xu, MD

Managing Director, Quan Capital

Stella Xu, Ph.D. has served as a member of our board of directors since August 2017. Dr. Xu has served as a managing director of Quan Capital since August 2017. Prior to that, Dr. Xu served as vice president and site head of Roche Innovation Center Shanghai and as a member of the global management team for Roche’s Infectious Diseases Discovery and Translation Area beginning September 2012, and for Immunology, Inflammation & Infectious Diseases Discovery and Translation Area beginning March 2016, to June 2017. Dr. Xu received her B.S. in Biophysics from Peking University and her Ph.D. in Immunology from Northwestern University. We believe Dr. Xu is able to make valuable contributions to our board of directors due to her experience as an investor and senior executive in the life sciences industry.

Peter Van Vlasselaer, PhD

Founder, President and Chief Executive Officer, ARMO BioSciences

Peter Van Vlasselaer, Ph.D. is our co-founder and has served as our president and chief executive officer and as a member of our board of directors since December 2012. Previously, Dr. Van Vlasselaer served as the interim president, chief executive officer and on the board of directors of iPierian, Inc. from April 2011 to August 2011, and continued to serve on the board of directors until April 2014. From March 2007 to January 2011, Dr. Van Vlasselaer was the president and chief executive officer of Arresto BioSciences, Inc. Previously, Dr. Van Vlasselaer was the chief executive officer of Avidia, Inc. from May 2004 until it was acquired by Amgen Inc. in October 2006. Prior to that he served as senior vice president of technical operations of InterMune Inc. from November 1999 until May 2004. He served as vice president of development of Dendreon Corp. from June 1993 to August 1999. From July 2013 to its acquisition in June 2017, Dr. Van Vlasselaer served as the executive chairman of the board of directors of True North Therapeutics, Inc. Dr. Van Vlasselaer also serves on the board of directors of Blade Therapeutics, Inc. and as the chairman of the board of directors of TM3 Therapeutics B.V., both of which are private biopharmaceutical companies. Dr. Van Vlasselaer received a B.S. in Zoology and a Ph.D. in Cellular Immunology from the Catholic University of Leuven in Belgium.